Cleveland BioLabs Reports Positive Effects of Chemotherapeutic Drug
Posted on: Wednesday, 20 February 2008, 12:02 CST
Cleveland BioLabs has reported encouraging results of a study that demonstrated Protectan CBLB502's ability to reduce the side effects of a chemotherapeutic drug, cisplatinum, broadly used for treatment of many types of cancer.
In the study, CBLB502 was injected 30 minutes before cisplatinum at a dose of 1mcg/mouse (0.04mg/kg, which is less than 1% of maximal tolerable dose). Cisplatinum was injected either at maximal tolerable dose or at double maximal tolerable dose. In mice that received the maximal tolerable dose of cisplatinum, CBLB502-pretreated animals showed neither weight loss nor behavioral signs of morbidity, both of which were seen in all of the control group mice.
Cleveland BioLabs plans to initiate a Phase I/II study in the first half of 2008 for CBLB502 in head and neck cancer patients for reduction of side effects of radiation and chemotherapy, such as mucositis, which can be a treatment-limiting factor.
Source: Datamonitor
Related Articles
- Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
- Transition Therapeutics Initiates Dosing in Phase II Diabetes Study
- PolyMedix Initiates Dosing for Phase I Systemic Infections Study
- Palatin Initiates Dosing in Phase IIa Hypertension Study
- Semafore and Multiple Myeloma Research Consortium (MMRC) Dose First Patient in Phase I Study of Targeted PI3 Kinase (PI3K) Inhibitor
- Pharmasset Commences Dosing in 28-Day Combination Study of R7128 With Pegasys(R) Plus Copegus(R) for Hepatitis C
- TargeGen Eye Drop Well Tolerated in Human Study
- Athenagen's Eye Drop Therapy for AMD Is Safe and Well Tolerated in Phase I Study
- Nastech Begins Dose-Ranging Obesity Nasal Spray Study
- Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain
 |
 |
User Comments (0)
RSS Feeds